Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 5/20 | 0.53 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18885406 | 1.00 | GPR88 (0.53) | GPR88GRM7POLBKCNQ2LMNA | |
| SCHEMBL14135235 | 0.86 | MEN1 (0.66) | GRM7POLBLMNAMEN1KMT2A | |
| SCHEMBL9559761 | 0.86 | GRM7 (0.51) | GPR88GRM7POLBKCNQ2LMNA | |
| SCHEMBL11196738 | 0.84 | GPR88 (0.50) | GPR88GRM7POLBLMNAL3MBTL1 | |
| SCHEMBL4156225 | 0.84 | MME (0.64) | GPR88GRM7POLBLMNAMME | |
| SCHEMBL24571811 | 0.84 | GPR88 (0.55) | GPR88GRM7POLBKCNQ2LMNA | |
| SCHEMBL24571671 | 0.84 | GPR88 (0.55) | GPR88GRM7POLBKCNQ2LMNA | |
| SCHEMBL24757742 | 0.83 | HDAC3 (0.61) | POLBLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2605721 | 0.82 | ALDH1A1 (0.55) | GPR88GRM7POLBKCNQ2LMNA | |
| SCHEMBL197183 | 0.82 | KEAP1 (0.58) | POLBLMNAMEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572823-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566289-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9549938-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9353133-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150119364-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2015-04-30 | — | — | US | disclosed |
| US-7767657-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-6117893-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 2000-09-12 | — | — | US | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206638-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
| US-20160151399-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
| US-20160228463-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
| US-20160184334-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
| US-20150119364-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | GPR88 3157/4885GRM7 4321/4885POLB 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.